Oncocross온코크로스
382150 · KOSDAQ · ₩382150 · 온코크로스
₩3,110▲ ₩60 (1.97%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | ₩370M | ₩1.1B | ₩92M |
| Cost of sales | — | ₩350M | ₩87M |
| Gross profit | — | ₩722M | ₩4.5M |
| Operating income | −₩8.8B | −₩7B | −₩6.8B |
| Net income | −₩8.9B | −₩6.5B | −₩4.2B |
| Net income to shareholders | −₩8.9B | −₩6.5B | −₩4.2B |
Balance sheet
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total assets | ₩29B | ₩23B | ₩18B |
| Current assets | ₩24B | ₩21B | ₩17B |
| Cash and equivalents | ₩2.8B | ₩15B | ₩12B |
| Total liabilities | ₩16B | ₩2.1B | ₩1.1B |
| Current liabilities | ₩5.8B | ₩1.8B | ₩1.1B |
| Borrowings | ₩5B | ₩636M | ₩742M |
| Total equity | ₩13B | ₩20B | ₩16B |
| Shareholders' equity | ₩13B | ₩20B | ₩16B |
Cash flow
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Cash from operations | −₩7.4B | −₩5.5B | −₩4.9B |
| Free cash flow | −₩7.4B | −₩5.5B | −₩4.9B |
Consolidated where available. Amounts in won.
Also known as: Oncocross / 온코크로스 / 382150 / KRX:382150
Source: KRX statistical information